Since PI3K/AKT mainly promotes the Cisplatin resistance in different tumors, suppression of this pathway through the RTK, PI3K, and mTOR inhibitors or specific miRNAs can be efficient methods to overcome the CDDP resistance and improve the quality of life in cancer patients. Here, AKT1 is linked to cancer.